By The Burrill Report:
By Michael Fitzhugh
Teva Pharmaceutical Industries (TEVA) rang in the New Year by announcing that Jeremy Levin, a former senior executive at Bristol-Myers Squibb (BMY), will succeed Shlomo Yanai as president and CEO of the Israeli drug giant.Levin, who joined BMS in 2007, was responsible for strategy, alliances, and transactions there. He also logged time at Novartis as its global head of business development and strategic alliances. Prior to that, he took the ill-fated Cadus Pharmaceuticals public as CEO in 1996.Levin, who was born in South Africa, has lived in the United States since 1986. He has also lived in Zimbabwe, Great Britain, Switzerland, and Israel. A graduate of Oxford and Cambridge universities, he says he has admired Teva for many years.“Demographic trends and economic pressures in developed and emerging markets are intensifying the challenge to provide good medicines at affordable prices,” he says. “Teva, with itsComplete Story »